COMMUNIQUÉS West-GlobeNewswire

-
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30/04/2024 -
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30/04/2024 -
EAACI Congress 2024: Innovation and Advances in Allergy Treatment
30/04/2024 -
Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies
30/04/2024 -
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
30/04/2024 -
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
30/04/2024 -
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30/04/2024 -
BioSenic S.A. : Information on the total number of voting rights and shares
30/04/2024 -
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
30/04/2024 -
Combined General Meeting of May 22, 2024 - Availability of preparatory documents
30/04/2024 -
Assemblée Générale mixte du 22 mai 2024 - Modalités de mise à disposition ou de consultation des documents préparatoires
30/04/2024 -
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
30/04/2024 -
Stride Autism Centers Hosts Open House in Downers Grove, IL
30/04/2024 -
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
30/04/2024 -
Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
30/04/2024 -
Aurora Spine Corporation Announces Fourth Quarter and Fiscal 2023 Financial Results
30/04/2024 -
Mustang Bio Announces Pricing of $4 Million Public Offering
30/04/2024 -
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
30/04/2024 -
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
30/04/2024
Pages